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Abstract
Despite increased risk of a recurrent stroke following a minor stroke, information is minimal regarding the interaction
between injurious mild cerebral ischemic episodes and the possible treatments which might be effective. The aim of the
current study was to investigate recurrent ischemic stroke and whether resveratrol, a nutritive polyphenol with promising
cardio- and neuro- protective properties, could ameliorate the associated brain damage. Experiments in adult rats
demonstrated that a mild ischemic stroke followed by a second mild cerebral ischemia exacerbated brain damage, and,
daily oral resveratrol treatment after the first ischemic insult reduced ischemic cell death with the recurrent insult (P,0.002).
Further investigation demonstrated reduction of both inflammatory changes and markers of oxidative stress in resveratrol
treated animals. The protection observed with resveratrol treatment could not be explained by systemic effects of
resveratrol treatment including effects either on blood pressure or body temperature measured telemetrically. Investigation
of resveratrol effects on the blood-brain barrier in vivo demonstrated that resveratrol treatment reduced blood-brain barrier
disruption and edema following recurrent stroke without affecting regional cerebral blood flow. Investigation of the
mechanism in primary cell culture studies demonstrated that resveratrol treatment significantly protected endothelial cells
against an in vitro ‘ischemia’ resulting in improved viability against oxygen and glucose deprivation (39.666.6% and
81.369.5% in vehicle and resveratrol treated cells, respectively). An inhibition of nitric oxide synthesis did not prevent the
improved cell viability following oxygen glucose deprivation but SIRT-1 inhibition with sirtinol partially blocked the
protection (P,0.001) suggesting endothelial protection is to some extent SIRT-1 dependent. Collectively, the results
support that oral resveratrol treatment provides a low risk strategy to protect the brain from enhanced damage produced
by recurrent stroke which is mediated in part by a protective effect of resveratrol on the endothelium of the
cerebrovasculature.
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Introduction
Thrombo/embolic ischemic stroke is a leading cause of death
and long-term neurological disability. An important population of
patients at risk of stroke is one that has had a transient ischemic
attack (TIA) or minor stroke. In these patients cerebral vessel
occlusion is of short duration and its recannalization is followed by
near or complete functional recuperation. Despite functional
recovery, there is limited knowledge concerning the extent of full
tissue recovery. There is increasing evidence that there can be
ischemic damage not always detectable with standard diagnostic
imaging techniques. Health status of the brain is likely crucial in
these patients considering they are at higher risk of a recurrent
stroke, with stroke recurrence being reported in 6–15% of patients
within 90 days and in up to 21% of patients by one year post initial
insult [1,2]. The degree of cerebral recovery can likely affect the
brain’s susceptibility to a second ischemia. Indeed, we have
observed this in our novel model of recurrent stroke in the rat
which incorporates a transient middle cerebral artery occlusion
(MCAO) (e.g. a TIA or mild stroke) followed by a second occlusion
with recannalization [3]. We found that an MCAO of short
duration (mild ischemic stroke) can result in scattered necrosis not
well detected with standard MRI and such an insult followed by a
subsequent moderate stroke had exacerbated damage [3]. This
was different from the preconditioning protection observed with a
mild ischemic insult that does not produce permanent damage [4]
and little is known about the interaction of multiple insults causing
mild damage or minor stroke. Also unknown is the potential
effectiveness of treatments administered after an initial insult and
prior to a recurrent insult. The dietary polyphenol resveratrol
(3,49,5-trihydroxystilbene), found naturally in foods such as
berries, nuts, and grape skins has been considered a highly
promising treatment for recurrent stroke in light of its documented
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range of beneficial cardiovascular and neurological benefits [5–11]
with minimal side effects [12].
Thus, in the present study we used a novel model of recurrent
stroke in the rat to investigate the interaction between multiple
mild ischemic insults and the effects of resveratrol treatment. The
results demonstrate that brain damage is enhanced when a mild
recurrent ischemic stroke follows an initial mild ischemic insult.
Oral administration of resveratrol between insults was found to
reduce ischemic cell death. The beneficial effects of resveratrol
treatment were not related to altered regulation of systemic blood
pressure, body temperature or regional cerebral blood flow (CBF)
but are consistent with it acting, at least partially, via beneficial
effects on endothelial function.
Results
Significant Levels of Resveratrol in Blood and Tissues
Following Oral Treatment
Experiments were performed to investigate the concentrations
of resveratrol in blood and tissues following oral resveratrol
administration. Significant levels of resveratrol were detected using
high performance liquid chromatography tandem mass spectrom-
etry (LC/MS/MS) in the plasma and tissues of resveratrol treated
animals; levels reaching a peak that fell quickly soon after feeding
(Fig. 1 A). Resveratrol was detected in significant amounts in liver
and brain homogenates of treated rats following daily doses
(25 mg/kg/day) for four doses (Fig. 1 B). Small amounts of
resveratrol were also detected in the tissue of control animals,
consistent with the modest levels of resveratrol present in the
regular lab rat diet.
Enhancement of Cell Death by Recurrent Stroke and its
Reduction by Resveratrol
Of the 42 animals randomized to MCAO, six died as a result of
surgical complications. During MCAO all animals had .90%
reductions in cortical perfusion as measured in the core region
using a single laser Doppler probe. A mild ischemic stroke
produced cortical injury and scattered cell necrosis evident seven
days post-insult (Fig 1 C). The damage observed following
recurrent mild stroke was more severe often consisting of regions
of infarct and this was reflected in a higher damage score (P,0.05)
(Fig.1 D).
Oral treatment with resveratrol for three days prior to a single
mild stroke, reduced the extent of damage observed compared
with vehicle treated animals (Fig 1 C, D). Similarly, in resveratrol
treated animals that were administered resveratrol immediately
following the initial insult and for three more doses on each of the
next three days, there was a reduced damage score and enhanced
protective effect compared to vehicle treated animals (Fig. 1 D).
Lack of Resveratrol Mediated Alterations in Physiological
Variables that Potentially Affect Stroke Outcome
The effects of resveratrol on physiological parameters poten-
tially affecting ischemic stroke outcome were investigated carefully.
During MCAO, blood glucose, mean arterial blood pressure,
PO2, PCO2, PH, and tympanic temperature were similar between
groups (Table 1). All rats recovered well from both single and
recurrent stroke procedures with a similar gain in weight in
resveratrol and vehicle treated animals. At the time of MCAO,
laser Doppler flow measured within the core (proximal parietal
cortex) ipsilateral to the occlusion decreased to: 8.061.8% and
8.662.7% of baseline in the vehicle and resveratrol treated single
mild stroke groups; 8.263.2% and 6.462.6% in the vehicle and
resveratrol treated recurrent stroke groups (first mild stroke);
9.464.2% and 8.661.1% in the vehicle and resveratrol treated
recurrent stroke groups (second mild stroke), respectively. No
significant differences were found in the flows detected either in
the proximal or distal cortical regions between resveratrol and
vehicle treated groups at either onset or end of ischemia. Five
minutes following removal of all three clips on the arteries, blood
flow in the ipsilateral parietal cortex proximally returned to greater
than pre-occlusion levels (range of 114 to 141%) and were not
different between groups (data not shown). Similar responses were
observed distally (means of 128.5, 132.2, 116.8 and 114.6% of
initial flow in the recurrent vehicle, recurrent resveratrol, single
vehicle and single resveratrol groups, respectively; data not
shown).
Despite a lack of evidence for acute physiological differences
during MCAO in the anesthetized animals, it was possible that
resveratrol had systemic effects which could be more readily
detected in conscious animals. There has been evidence suggesting
that resveratrol can affect blood pressure [6,13,14] or body
temperature [15], although such findings have not been consistent
[16]. Thus, in additional groups of unanesthetized animals, we
further investigated the systemic circulatory and temperature
control effects of daily resveratrol administration using implanted
telemetry probes. In these animals, resveratrol treatment did not
alter telemetrically measured heart rate, mean arterial blood
pressure or core temperature at any time points prior to or
following resveratrol treatment compared with vehicle treated
controls (Fig. 2 A–C).
Reduction of Markers of Inflammatory Changes and
Nitroxidative Stress with Resveratrol Treatment
Next we considered whether resveratrol had beneficial effects on
signs of inflammation or oxidative stress following mild or
recurrent ischemic stroke. Using immunohistochemistry, we
assessed alterations in staining for reactive astrocytes using anti-
glial fibrillary acidic protein (GFAP), alterations in staining for
microglia/macrophage reactivity using anti-ED1, and altered
oxidative stress using immunostaining with anti-nitrotyrosine (NT),
a product of free radical oxidation of nitric oxide [17,18].
Following a mild ischemic stroke, sections immunostained with
GFAP demonstrated areas of increased astrogliosis in peri-infarct/
penumbral regions- an effect which was enhanced with recurrent
stroke (Fig. 3 A). The group of animals treated with resveratrol
between their initial and recurrent stroke demonstrated significant
reductions in areas of altered astrocytic GFAP staining compared
with the vehicle treated group (P,0.001).
Following a mild ischemic stroke, there was increased ED1
staining of microglia/macrophages evident within the ischemic
core and peri-infarct/penumbral regions (Fig 3 B). Quantitative
assessment demonstrated that in animals with recurrent stroke
there was a reduced cumulative staining score for ED1 compared
with vehicle treated animals (P,0.008) suggestive of a reduced
inflammatory response.
Similar to ED1, NT staining was increased ipsilaterally in the
ischemic region following either a mild or recurrent ischemic
stroke (Fig 3 C). In resveratrol treated animals with recurrent
stroke there was a significant decrease in staining for NT in the
ischemic cortex ipsilaterally (P,0.009) suggestive of a reduced
production of nitroxyl radicals in the brains of resveratrol treated
animals with recurrent stroke.
Resveratrol Protection against Recurrent Stroke
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Resveratrol Does Not Alter Local Regional CBF During or
After Recurrent Stroke but does improve BBB function
The mechanisms causing stroke injury are complex and
maintenance or restoration of tissue perfusion and vascular
integrity may be key for mitigating complex neuroinflammatory
processes at the blood brain barrier precluding neuronal cell death
[19,20]. Various reports on vascular effects of resveratrol support
the possibility of enhanced vascular reactivity including improved
regional CBF or improved BBB integrity [7,10,21]. Thus we
performed additional experiments that investigated the effect of
resveratrol treatment on regional blood flow during and following
recurrent stroke measured with laser speckle imaging. Although
regional CBF was significantly reduced from baseline during
ischemia in all defined regions of interest (Regions 1–4; P,0.001)
and perfusion values differed between the different regions
examined, there were no significant differences between resvera-
trol and vehicle treated rats at any time point, in any region (Fig. 4
A, B).
In contrast to a lack of effect of resveratrol on CBF, there were
differences in BBB function in these same animals. Recurrent mild
stroke resulted in an increase in Evans Blue extravasation in the
cortex ipsilateral to the injury that was more marked in vehicle
compared to resveratrol treated rats (Fig. 4 C). Resveratrol
treatment significantly reduced the amount of Evans blue leakage
through the BBB (P,0.001; Fig. 4 D). Consistent with the changes
in vascular permeability, there were corresponding changes in
brain water content (Fig 4 E). Brain water content in the ipsilateral
compared with the contralateral cortex was significantly increased
in vehicle treated rats (P,0.04); whereas, resveratrol treated rats
did not have a significant increase in brain water content
ipsilaterally at 48 hours following the second stroke. Linear
regression between the average flow in Region 1 (the region
Figure 1. Mean (±SD) amounts of resveratrol (RSV) detected in the plasma (A), and liver and brain tissue (B), of naive animals
treated with daily oral doses of RSV (25 mg/kg). Hematoxylin and eosin stained sections (C) from scanned sections (left) and magnified insets
(20x; right) depict scattered cell death following a single mild stroke and extensive cell death following a recurrent stroke. Less cell death is observed
with RSV treatment. Quantitative assessment of damage as a cumulative injury score (D) demonstrated that there was reduced cell death in the RSV
treated groups compared with the respective vehicle (Veh) treated group in either proximal or distal cerebral cortex. Data presented as median (+/2
first and third quartile). Different from respective vehicle (Veh): +P,0.05 (ANOVA and Dunn’s Test), {P,0.05 or {{P,0.006 (Students t-test), *P,0.03
or **P,0.002 (ANOVA on ranks and Mann-Whitney Rank Sum Test).
doi:10.1371/journal.pone.0047792.g001
Resveratrol Protection against Recurrent Stroke
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within the window considered closest to the core) and the amount
of Evans Blue present in the tissue after 48 hours, showed that the
amount of BBB disruption was not predicted by either the blood
flow during ischemia (Fig 4 F, r =20.066; P= 0.804) or after 40
minutes of reperfusion (20–60 minutes of reperfusion, Fig 4 G,
r = 0.0889; P = 0.806). This suggests that the protective effect of
resveratrol treatment on the BBB is independent of the original
severity of ischemia and the magnitude of acute local reflow.
Resveratrol Protects Endothelial Cells against Oxygen
Glucose Deprivation Cell Death
The BBB is localized to cerebral endothelial cells in the cerebral
capillaries forming a lumen with tight junctions and specialized
transporters. Thus we next investigated whether resveratrol’s
effects could be studied directly in endothelial cells in vitro.
Resveratrol treatment of endothelial cells at low doses (0.1–1 mM)
for 3 days prior to exposure to oxygen glucose deprivation
increased cell viability (Fig.5 A, p,0.001) whereas higher doses
(.1 mM) were associated with reduced cell viability. To examine
potential pathways involved, the non-specific NOS blocker, (Nv-
Nitro-L-arginine methyl ester hydrochloride [L-NAME], 10 mM
or 50 mM), was investigated and found to not prevent the
improved cell viability following oxygen glucose deprivation.
However, the SIRT-1 blocker, sirtinol, partially blocked the
protection at a dose of 50 mM (P,0.001) (Fig. 5 B). This suggested
endothelial protection is, at least in part, SIRT-1 dependent.
Discussion
The major original finding of the current study is that
resveratrol treatment protects against brain injury in our new
model of mild recurrent stroke. In addition to a reduction in brain
injury, resveratrol treatment lessens oxidative stress and inflam-
mation, prevents edema, protects endothelial cells and preserves
BBB function following recurrent stroke, but does not alter
regional CBF or systemic variables such as blood pressure and
core temperature. The results support that a treatment such as
resveratrol is promising for its ability to reduce the severity of
damage due to stroke recurrence and could have a significant
impact on quality of life and associated costs of caring for stroke
survivors.
We show for the first time protection with resveratrol against
ischemic brain injury due to recurrent mild stroke. We also
observed protection with pre-treatment prior to a single mild
stroke which is consistent with what has been found with
resveratrol pre-treatment in other stroke models [5,11,22].
Resveratrol treatment between mild ischemic strokes also reduced
signs of activated astrocytes, reactive nitrogen species, and
microglia/macrophage activation suggesting that resveratrol
interferes with oxidative and/or inflammatory processes in
recurrent stroke, although these effects could be secondary to
upstream actions such as activation of SIRT1 deacetylase. This
limitation could be addressed in future studies examining more
directly the role of these and additional markers of inflammation
and oxidative stress. Rather unexpected was our finding that
resveratrol-treated rats subjected to recurrent stroke had less
ischemic injury than untreated rats with a single mild ischemic
stroke. As resveratrol treatment did not begin until one hour after
reperfusion from the first stroke, our results indicate beneficial
post-treatment effects of resveratrol as well as a pre-treatment
effect. Post-ischemic administration of RSV has not been as
extensively studied but there is some evidence for protection with
post-ischemic administration [9,23]. Resveratrol having beneficial
pre-treatment and post-treatment effects likely contributes to its
significant effectiveness in the recurrent stroke model and increases
its potential for providing a robust treatment in stroke patients.
Resveratrol has been widely studied but its mechanisms of
action are still controversial and poorly defined, including
identification of the potential cardiovascular or systemic effects
that may modify cerebral ischemic injury or recovery. Determin-
ing cardiovascular impact is essential for a better understanding of
resveratrol’s mode of protection because even minor stroke may
lead to effects such as impaired cerebral autoregulation to blood
pressure changes [24]. There is evidence in mice that resveratrol
treatment has little effect on heart rate [16]. The present study,
using continuous telemetric measures in conscious animals,
confirmed a lack of effect of resveratrol treatment on heart rate
under baseline conditions prior to stroke but also during and post
Table 1. Mean+ body temperature and arterial blood gas values during and following either a single mild stroke or a first and
second recurrent stroke.
Stroke Type Treatment Temperature (6C) PO2 (mm Hg) PCO2 (mm Hg) pH
During Reperf During Reperf During Reperf During Reperf
Mild Stroke Veh 36.4 36.6 102 101 49.5 45.3 7.31 7.34
60.3 60.2 67 623 614 615 60.08 60.09
Mild Stroke RSV 36.5 36.8 128 111 36.2 39.4 7.4 7.37
60.2 60.4 638 62 64 67 60.02 60.03
Recurrent 1st Veh 36.5 36.7 110 109 42.7 43.8 7.36 7.33
60.4 60.4 611 620 63 63 60.05 60.06
Recurrent 2nd Veh 36.4 36.7 110 102 40.6 50.9 7.37 7.33
60.4 60.5 612 626 69 66 60.05 60.01
Recurrent 1st RSV 36.4 36.6 118 123 38 38 7.41 7.37
60.3 60.3 625 627 65 62 60.04 60.03
Recurrent 2nd RSV 36.4 36.6 117 124 37.6 42.4 7.41 7.39
60.3 60.3 620 618 65 612 60.04 60.06
+data presented as mean6SD (n = 3-6), n.s. Mean hematocrits – 35-40. Abbreviations: Reperf – Reperfusion, Veh- Vehicle, RSV – resveratrol.
doi:10.1371/journal.pone.0047792.t001
Resveratrol Protection against Recurrent Stroke
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cerebral ischemia. Furthermore, we demonstrated that resveratrol
treatment has no appreciable effect on blood pressure before,
during, or after a mild ischemic stroke. Body temperature is
another critical factor influencing stroke outcome with ischemic
brain injury being exquisitely sensitive to even small changes in
temperature [25–27]. A small (,0.5uC) increase in body
temperature has been observed in mice in the first 3 of 7 days
of resveratrol treatment [16]. We detected no alterations in body
temperature in rats treated with resveratrol before, during or after
a mild ischemic stroke. Taken together, the overall lack of
cardiovascular and systemic (e.g. temperature) effects of resveratrol
both during ischemia and reperfusion suggest that cerebral rather
than peripheral changes underlie the protection afforded by
resveratrol in young rats.
In addition to the parenchymal protection observed, resveratrol
was investigated for its potential to improve the health of the
cerebral microvasculature during and after stroke. Microvessel
health is essential to neuronal survival and requires preservation of
vessel reactivity, adequate cerebral perfusion and optimal BBB
function and its associated neurovascular exchange. We found no
evidence for resveratrol-mediated augmentation of vascular
responsiveness and flow in the ischemic area, during or after
ischemic stroke using focal measures of laser Doppler flowmetry or
measures of regional CBF with laser speckle imaging. However,
we did demonstrate a substantial reduction in BBB disruption and
a suppression of edema following recurrent stroke in resveratrol-
treated rats that was independent of flow changes.
Several mechanisms may be involved in the protection of the
BBB. BBB dysfunction following ischemia is associated with
changes in tight junction proteins such as occludin and claudin
involving mediators such as matrix metalloproteinases (MMPs)
that cause degradation of these tight junction proteins[28,29].
Studies indicate that resveratrol inhibits increases in MMP
expression following oxygen glucose deprivation in vitro or
cerebral ischemia in-vivo[30,31]. Another study has reported
protection by resveratrol of the damage to microtubule cytoskel-
eton and tight junctions in cultured cerebral endothelial cells
produced by their treatment with oxidized low-density-lipopro-
teins[32]. In addition, we found that pre-treatment of brain
endothelial cells in culture with low doses of resveratrol improved
their viability following oxygen glucose deprivation which could
also explain improved BBB function following cerebral ischemia.
Improved viability is consistent with the resveratrol-mediated
protection of cerebral endothelial cells against apoptosis induced
by oxidized low-density lipoproteins [33]. It is also consistent with
the demonstrated protection of cardiac endothelial cells against
death or injury produced by high glucose induced oxidative
stress[34,35]. In these cardiac endothelial cells, resveratrol
attenuated oxidative stress that was shown to involve the activation
of SIRT1 and upregulation of antioxidant defense mechanisms
mediated by activation of nuclear factor-E(2)-related factor-2. We
also found that resveratrol-mediated protection against oxygen
glucose deprivation in endothelial cells is at least partially
dependent on SIRT1 activation and in brain is associated with a
reduction in NT indicative of an inhibition of nitroxidative stress.
Thus improved blood brain barrier function observed in vivo is
likely due to a combination of resveratrol’s inhibition of MMPs,
reduced degradation of tight junction proteins, reduced oxidative
stress, and improved endothelial cell viability. Further study is
required to demonstrate their relative importance and the extent
to which protection of endothelial cells, a key component of the
neurovascular unit, benefits neuronal function and viability.
To conclude, the current results indicate that a recurrent stroke
consisting of two mild transient ischemic episodes produces
damage exceeding that of a single mild stroke. Resveratrol
administered at moderate doses and within a clinically relevant
acute time frame of three days reduces parenchymal brain damage
and inflammation produced by either a single or a recurrent mild
stroke. These beneficial effects of resveratrol treatment appear
related at least partially to a reduced BBB extravasation and
Figure 2. Telemetric measures of heart rate (A), mean arterial
blood pressure (B) and body temperature (C). Mean (6SD) values
were similar in resveratrol (RSV, 25 mg/kg/day for 4 doses) and vehicle
(Veh) treated rats at all times for 24 hr prior to treatment, for 3 days
during treatment (prior to a mild stroke) and during the 48 hr of
monitoring thereafter.
doi:10.1371/journal.pone.0047792.g002
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cerebral edema associated with improved viability of endothelial
cells against deprivation of substrate and oxygen delivery. The
results support further investigation of the protective role of
resveratrol treatment as a dietary supplement that could poten-
tially provide a low risk and effective option for protective therapy
in patients following their first TIA or minor stroke.
Materials and Methods
Ethics Statement
For experiments conducted in Calgary, animals were used and
handled in accordance with the Canadian Council on Animal
Care and University of Calgary Health Sciences Animal Care
Committee (Approved Protocol MO7073). For laser speckle flow
and blood-brain barrier (BBB) experiments conducted in Szeged,
Hungary, all experimental procedures were approved by the
Ethical Committee for Animal Care of the University of Szeged,
Szeged, Hungary. All animals were randomized to their treatment
groups and the surgeon and investigators performing analysis were
blinded to the treatments.
Bioavailability of Resveratrol
Resveratrol levels in blood and tissue were first assessed using
LC/MS/MS in 200–300 g male Wistar rats (Charles River,
Montreal, Canada) treated with either trans-resveratrol (25 mg/kg
p.o, n= 3) or vehicle (n = 3). Blood samples were obtained in
anesthetized rats at various time points (10, 20, 30, 60, 120 min)
following daily treatments and the plasma was frozen for analysis.
Two hours after the last (fourth) treatment, samples of brain and
liver were dissected on ice, homogenized in lysis buffer,
centrifuged at 5000 g for 15 min, and the supernatant was frozen.
The sample preparation and analysis was as described previously
with some modifications [36]. Briefly, proteins in samples (200 mL)
were precipitated using 400 mL of EtOH with internal standard
(resveratrol-phenyl-13C6, Sigma-Aldrich Co. Oakville, Canada).
The supernatant was dried and then reconstituted in 200 mL of
50:50 acetonitril:1 mM ammonium formate. The LC/MS/MS
analysis was carried out with an Agilent 1100 HPLC (Agilent
Technologies, Palo Alto, USA) coupled to an API 4000 triple
quadrupole Mass Spectrometer equipped with a Turbo-Ionspray
Interface (AB Sciex, Concord, Ont., Canada). Resveratrol was
separated using a 2.16100 mm, 5 m Hypersil ODS column
Figure 3. Representative brain sections depicting resveratrol (RSV) effects on glial activation, microglial/macrophage activation
and nitrosative stress using respective immunostaining for: A - glial fibrillary acidic protein (GFAP), B – ED1 and C - nitrotyrosine
(NT). Staining was assessed as the mean (6SD) area of altered GFAP stain presented as a percentage of the contralateral hemisphere or according to
a median cumulative damage score (+/2 first and third quartiles) of altered NT and ED1 staining. Significant RSV and vehicle (Veh) treatment
differences were detected between respective stroke groups. ** P,0.005 (ANOVA and Student-Newman Keuls Test), ++ p,0.005 (ANOVA and Mann-
Whitney Rank Sum Test).
doi:10.1371/journal.pone.0047792.g003
Resveratrol Protection against Recurrent Stroke
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(Agilent Technologies, USA). The mobile phase composed of
1 mM ammonium formate (A) and acetonitrile (B) was delivered at
a flow rate of 0.3 mL/min. A binary gradient started with 85% of
A and 15% of B, which was then increased to 50% of B at 6 min.
and subsequently to 70% of B at 8 min. Then, the column was
equilibrated with 15% of B for 10 min before the next 5 mL
sample injection. The mass spectrometer was operated in negative,
multiple reaction monitoring mode with the following settings:
source temperature 350uC, curtain gas 10, collision gas 6, gas1 50,
gas2 50, and ion spray voltage 24200 V. Quantitation of trans-
resveratrol (Sigma-Aldrich Co) was achieved using the 227/185
transition with the 227/143 transition monitored as confirmation
ion. Transitions monitored for internal standard (resveratrol-
phenyl-13C6) were 233/149 and 233/191.
In vivo stroke model and resveratrol treatment
Thirty rats were randomized to receive either single mild
(30 min transient MCAO, n= 16) or recurrent mild stroke
(2630 min transient MCAO, n= 14). Animals receiving a single
stroke were further randomized to receive, daily for 3 days prior to
the stroke, either vehicle (p.o., 17% Jello powder in water, n = 9) or
trans-resveratrol in vehicle (25 mg/kg p.o. Sigma-Aldrich, Oak-
ville, Ont, Canada, n= 7), the dose being within ranges used
previously [5,7,9] (Fig.1 A). Animals designated to receive
recurrent stroke were also randomized to receive resveratrol
(n = 7) or vehicle (n = 7) daily for three days, but the first dose was
administered 1 hour following the initial stroke and the final dose
1 hour prior to the second stroke. In ten additional animals, a lack
of a significant effect of sham surgery was confirmed by comparing
the injury in animals undergoing a mild ischemic stroke (n = 5) to
those that underwent a sham procedure involving surgical
isolation of the MCA followed by a mild ischemic stroke 3 d later
(n = 5).
Transient focal ischemia was achieved by placing a microan-
eurysm clip (Codman, size#1) on the middle cerebral artery
through a small burr hole in the skull, as previously described, with
some modifications [3]. Briefly, the animal was anesthetized with
isoflurane. Tympanic membrane temperature was maintained
using a servo-regulated overhead heating lamp at 36.0uC,
corresponding to approximately 37.0–37.5uC body temperature.
The tail artery was cannulated to continuously monitor arterial
blood pressure and obtain blood samples for determination of
blood gas and glucose levels during the procedure. Both common
carotid arteries were isolated and then an incision was made in the
temporalis muscle. The skin and muscle were retracted to expose
the skull. A small craniotomy was made at the point where the
MCA crossed the rhinal fissure. Prior to removing the dura over
the MCA, two additional burr holes were made to allow for
measurement with laser Doppler flowmetry. One hole was made
3 mm dorsal to the site of the MCA (referred to as proximal) and
other 3 mm posterior to the first hole (referred to as distal). The
dura was removed to expose the MCA which was subsequently
occluded with the microaneurysm clip. Concurrently, both
common carotid arteries were occluded using vascular clamps.
Blood flow reduction was confirmed with laser Doppler flowmetry.
Animals were excluded if the criterion of 90% blood flow
reduction in the core was not met. At the end of the 30 min
occlusion, the microclip was removed and the carotid artery
clamps were removed. For animals that were to undergo a second
stroke, artificial dura (Gore Preclude MVP, Better Hospital
Supplies Corp., Miami, FL) was placed over the exposed MCA
to minimize adhesion to the vessel and fibrosis infiltration. All
wounds were securely sutured and topical anesthetic was applied
(Lidocaine). Analgesia (0.03 mg/kg buprenorphine s.c) was
administered and animals were monitored closely during recovery.
Three days later, rats to receive recurrent stroke underwent
transient MCAO in a similar manner as described above. The
position of the second clipping of the MCA was immediately
dorsal to the original clip position to minimize trauma to the
vessel. Following surgery rats were given softened food in order to
minimize weight loss (,10%).
Telemetry Measurements
To simultaneously monitor core temperature, heart rate and
mean arterial blood pressure in awake and freely moving rats we
used telemetry probes (TML2 C50-PXT, Transoma Medical, St
Paul, MN, USA). These were implanted abdominally using aseptic
techniques under isoflurane anesthesia. Two leads from the probe,
tunneled under the skin, measured heart rate and a catheter
inserted into the descending aorta without obstructing blood flow
measured arterial blood pressure. After 1 week of recovery,
animals were placed in separate cages, allowing measurements to
be recorded every 30 sec via RPC-1 receivers (Transoma
Medical). Following 24 h of baseline measurements, rats were
fed vehicle (n = 3) or 25 mg/kg RSV (n= 3) daily for 4 doses. One
hour following the final dose, rats were subjected to a single mild
stroke as described above. After recovery animals were further
monitored using telemetry for 48 h following stroke.
Histological Assessment of Cell Death, Microglial
Activation and Nitroxyl Radicals
One week after the either the single stroke or the 2nd insult of
recurrent stroke, animals were perfused with 10% formalin under
anesthesia. Brains were embedded in paraffin and 6 mm sections
were stained with hematoxylin and eosin to determine cell death.
Standard infarct volume assessment did not allow us to accurately
evaluate the scattered cell death that we observed following mild
stroke; therefore, a cumulative score for brain injury at each level
was assessed by an investigator blinded to the animal identity. A
scoring system similar to that used previously [3] was used to
determine the extent of injury. The cortical hemisphere was
divided into 4 areas of interest that were scored from 0–4 as
Figure 4. Representative color-transformed laser speckle difference images (A) showing regional perfusion changes relative to
baseline values for an animal during recurrent mild stroke that was produced three days following an initial mild stroke. Perfusion
values were assessed in four different regions (1 to 4) for each animal according to positions relative to the site of middle cerebral artery occlusion
(arrow). Mean perfusion values were similar in resveratrol (RSV) and Vehicle (Veh) treated rats for all regions at all time points with mean values for
Region 1 shown in Panel B. In the same animals, blood brain barrier function was assessed with Evans Blue and (C) shows representative coronal slices
of brain from rats treated with resveratrol (RSV) and Vehicle (Veh) showing greater Evans Blue extravasation indicative of BBB dysfunction in Veh
treated rats. The amount of Evans Blue present in the cortex was quantified using fluorescent spectrometry (E) and RSV-treated rats had significantly
less Evans Blue extravasation in the ipsilateral cortex compared with Veh-treated rats. Resveratrol treatment also prevented edema, as only Veh-
treated rats showed a significant increase in cortical brain water weight (F) on the injured side two days post-stroke. The extent of Evans blue
extravasation was not correlated to the regional perfusion changes (e.g. in Region 1), either during recurrent stroke (G) or after recurrent stroke (H),
indicating that blood-brain barrier disruption did not depend on acute flow differences between groups. * p,0.05, different from contralateral
(Student’s paired t-test). { p,0.001, different from Veh (ANOVA with a Student-Newman Keuls test).
doi:10.1371/journal.pone.0047792.g004
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follows: 0 for normal, 1 for ,10% of neuronal injury, 2 for 10–
50% neuronal injury, 3 for .50% neuronal injury and 4 for
confluent areas of pan necrosis.
Immunohistochemical staining was performed in adjacent
sections that were dewaxed and incubated first with 10% goat
serum, then primary antibody overnight, and then visualized using
the appropriate biotin-conjugated IgG (Jackson ImmunoResearch
Figure 5. Effect of resveratrol (RSV) treatment on cell viability of endothelial cell cultures exposed to oxygen-glucose deprivation
(OGD). Improved viability was observed in endothelial cells treated with RSV at low doses (A). A sirtuin-1 antagonist (sirtinol, ST), but not the nitric
oxide synthase inhibitor (L-NAME), partially inhibited the RSV protection in endothelial cells (B). * P,0.05; ** P,0.005 different from 0 mM or vehicle
(Veh). + P,0.001 different from 0.5 mM RSV alone. (ANOVA with a Student-Newman Keuls test).
doi:10.1371/journal.pone.0047792.g005
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Lab followed by incubation with peroxidase-congugated strepta-
vidin (HRP) (1:400, Dako) and diaminobenzidine (DAB, Sigma).
Reactive astrocytes were assessed using anti-glial fibrillary acidic
protein (rabbit anti-GFAP, 1:1000, Sigma). Inflammatory signs of
activated microglia/macrophages were assessed using anti-ED1
(mouse anti-rat CD68 clone ED1, 1:100, Serotec). Signs of
oxidative stress were assessed using rabbit anti-Nitrotyrosine (NT,
1:1000, Upstate Biotechnology, NY)) to detect the accumulation of
peroxynitrite metabolites indicative of damage related to reactions
with nitroxyl radicals. Antigen retrieval was performed prior to
incubation with primary antibodies by immersing slides in boiling
citrate buffer pH=6 for 10 mins for ED1 and NT.
Areas of altered staining were measured in GFAP stained
sections that were scanned digitally (Nikon COOLSCAN 5.0).
Areas of altered stain were corrected for edema by measuring the
contralateral area and the unaltered area of staining ipsilaterally
and presenting the difference as a percentage of the contralateral
area. The ED1 and NT sections were scanned and assigned scores
similar to the hematoxylin and eosin stained sections above, except
that increased levels of staining were scored in the four different
cortical areas as follows: 0 - no increase in staining, 1- modest
increase in ,25% of the area, 2 - modest increase in 25–75 of the
area and/or intense increase in ,25% of the area, 3 – modest
increase in .75% and/or intense increase in 25–75% and 4 –
intense increase in .75% of the area.
Laser Speckle Contrast Imaging and Analysis
Acute regional CBF with the production of the second stroke
was measured using laser speckle imaging in another group of 13
rats. Animals were exposed to recurrent stroke and treated with
either resveratrol (n = 7) or vehicle (n = 6), for the 3 days between
the first and second stroke. After carotid artery isolation, rats were
placed into a standard stereotaxic frame and the skull was exposed
with a midline scalp incision. The ipsilateral parietal bone was
carefully thinned with a water-cooled drill (Bien-Air, Sweden) and
covered with a UV-light cured doming (Permabond, UK) to
render the skull transparent. A lateral window was also prepared
to expose the distal MCA for clipping. Rats were placed under a
PeriCam PSI HD System (Perimed, Sweden), which utilizes a
built-in 70 mW laser diode to illuminate the cortical surface.
Blood perfusion in the scanned area was monitored using a
138861038 pixel CCD camera at a speed of 2 Hz. Ten minutes of
baseline was recorded, after which the 2nd 30 minutes transient
MCAO was performed as described above. Images were taken (2
per sec) during the entire ischemic period and for 1 hour of
reperfusion. Analysis of laser speckle images was performed using
PIMsoft; a PeriCam PSI dedicated software (Perimed, Sweden).
Maps of the speckle contrast value at each pixel of the image show
the pattern of blood flow on the cortical surface during imaging.
The mean perfusion of the parenchymal microcirculation was
calculated by measuring the average perfusion values in four
regions of interest of equal size and shape placed in four conserved
locations (labeled 1–4 in Fig. 4 A) within the ipsilateral cortex.
Measurement of BBB Permeability and Water Content
BBB integrity and water content were investigated in the same
animals as those used for measuring CBF changes. Blood brain
barrier permeability was assessed by measuring extravasated
Evans Blue dye in animals following exposure to recurrent stroke
and treated with either resveratrol (n = 7) or vehicle (n = 6). For
treatment, 4 ml/kg of 2% Evans Blue (Sigma, USA) in saline was
injected through the tail artery immediately prior to reperfusion
with the recurrent stroke. Rats were sacrificed 48 hours after
reperfusion by transcardial infusion of saline. Wet and dry weights
(dried at 60uC for 24 h) of the ipsilateral and contralateral cerebral
cortices were measured and the corresponding water content was
calculated by the formula: water content = 100% (wet weight–dry
weight)/wet weight.
Dry cortices were incubated overnight in formamide (5 ml/g
dry weight) and the amount of Evans Blue released into the
formamide was quantified by florescence spectrophotometry
(excitation 620 nm; emission 680 nm). Raw data were compared
with a standardized curve of known quantities of Evans Blue in
formamide. Results are presented in ng/g tissue.
Rat Brain Endothelial Cell Cultures
Plastics used for endothelial cultures were obtained from
Becton-Dickinson (BD Biosciences, San Jose, CA, USA). Dulbec-
co’s modified Eagle medium (DMEM), Neurobasal medium, B27
Supplement, 2-mercaptoethanol, and fetal bovine serum were
obtained from Invitrogen (Carlsbad, CA, USA) and fetal bovine
plasma-derived serum was purchased from Animal Technologies
(Tyler, TX). Dispase I was purchased from Roche (Mannheim,
Germany) and Collagenase type II was obtained from Worthing-
ton (Lakewood, NJ). CellTiter 96 AQueous One Solution Assay was
acquired from Promega (Madison, WI, USA).
A total of 3 Wistar dams and 22 pups were used for endothelial
cultures. Rat brain endothelial cells were isolated from two week
old Wistar rat pups (Charles River Laboratories [Montreal,
Canada]), as described previously [37,38]. The cortices were
separated from meninges, then homogenized, and digested. The
homogenate was mixed with 20% BSA and centrifuged at 1,000 g
for 20 min to isolate cortical microvessels. Microvessels were
washed in DMEM, further digested, layered on a continuous 33%
Percoll gradient, and centrifuged at 1,000 g for 10 min. Endo-
thelial cells formed an easily distinguishable band that was
aspirated and washed twice with DMEM. The cells were then
seeded onto collagen IV- and fibronectin-coated 96-well plates.
Endothelial cell growth medium consisted of DMEM supplement-
ed with 2 mM glutamine, 20% fetal bovine plasma-derived serum,
50 mg/ml endothelial cell growth supplement, 100 mg/ml heparin,
1 ng/ml basic fibroblast growth factor, 5 mg/ml vitamin C, and
various antibiotics. Purity of endothelial cell cultures was ensured
by treating cells with puromycin (3 mg/ml) for three days as
described and validated by Perriere et al. [39] and was also
confirmed for each plate by visual inspection of cell morphology.
Experiments were carried out on days 3–7 in vitro.
An ischemic type insult sufficient to evoke ,50% cell death was
produced using oxyygen and glucose deprivation by washing the
cells and replacing the medium with glucose-free Dulbecco’s
modified Eagle medium (DMEM). This was followed by exposure
of the cells to a humidified anaerobic environment for 3.5 hours.
Control cell cultures were incubated under normal conditions in
glucose-containing DMEM.
Cell viability in the cultures was determined 24 hours after oxygen
glucose deprivation using the tetrazolium-based CellTiter 96 AQueous
One Solution assay. Absorbance at 490 nm was measured with a
microplate reader (FLUOstar OPTIMA, BMG Labtech GmbH,
Offenburg, Germany). Comparisons were made between cultures
treated in a similar way, with the exception of omitting the noxious
stimulus. Cell viability (%) was expressed as: (absorbancesample
2absorbancebackground6100/(absorbancecontrol2absorbancebackground).
Resveratrol’s effects were investigated in cell cultures treated
with various doses of resveratrol (100 nM-10 mM) dissolved in
culture medium containing up to 1.5% DMSO. Control cultures
were treated with 1.5% DMSO alone. Cells were treated once a
day (a new resveratrol solution was made each day) for three
consecutive days to match the in vivo treatment paradigm, and the
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medium was replaced with each new treatment. Alternatively, cells
were co-treated with resveratrol and 10 mM or 50 mM sirtuin-1
(SIRT1) inhibitor (sirtinol, Sigma) or the non-specific nitric oxide
synthase blocker (Nv-Nitro-L-arginine methyl ester hydrochloride
(L-NAME, Sigma).
Statistical Analysis
Differences between treatments were assessed with t-test or a
one-way analysis of variance (ANOVA) and a Student–Newman–
Keuls test. Non-parametric data were analyzed using a Kruskal
Wallis ANOVA on ranks and a Mann–Whitney rank sum test. A
value of P,0.05 was considered significant.
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